Interim Analysis of Repros Therapeutics Inc. Study of Androxal(R) in Men With Type 2 Diabetes Yields Statistically Significant and Clinically Relevant Reductions in HbA1c in Subset of Men Achieving Morning Testosterone > 450ng/dl

THE WOODLANDS, Texas, Aug. 3, 2011 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today provided unaudited top line results for an interim analysis it has performed on its Phase 2 clinical study of Androxal® in hypogonadal men with type 2 diabetes. Many men with secondary hypogonadism are also type 2 diabetic. Sixty-one (61) men have completed the three month dosing period and were the basis for this interim analysis. The study is being conducted at 19 clinical sites in the US. Enrollment of 110-120 subjects is expected to be completed by the end of August. Top line results for the full study should be available around year end 2011. The statistical analysis in this release was confirmed by an independent statistician.